Similarly, combining anti-PD1 antibody treatment with Wip1 deficiency in neutrophils more effectively reduced melanoma tumor growth compared with monotherapy with anti-PD1 or Wip1 deficiency alone (Fig. 6f). Here, PPM1D is linked to neoplasm.